Context Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell CNTX and other ETFs, options, and stocks.About CNTX
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers.
CEOMartin A. Lehr
CEOMartin A. Lehr
Employees12
Employees12
HeadquartersPhiladelphia, Pennsylvania
HeadquartersPhiladelphia, Pennsylvania
Founded2015
Founded2015
Employees12
Employees12
CNTX Key Statistics
Market cap107.50M
Market cap107.50M
Price-Earnings ratio-4.14
Price-Earnings ratio-4.14
Dividend yield—
Dividend yield—
Average volume213.46K
Average volume213.46K
High today$1.18
High today$1.18
Low today$1.09
Low today$1.09
Open price$1.12
Open price$1.12
Volume419.46K
Volume419.46K
52 Week high$1.89
52 Week high$1.89
52 Week low$0.49
52 Week low$0.49
Stock Snapshot
As of today, Context Therapeutics(CNTX) shares are valued at $1.16. The company's market cap stands at 107.5M, with a P/E ratio of -4.14.
During the trading session on 2025-11-15, Context Therapeutics(CNTX) shares reached a daily high of $1.18 and a low of $1.09. At a current price of $1.16, the stock is +6.9% higher than the low and still -1.7% under the high.
Trading volume for Context Therapeutics(CNTX) stock has reached 419.46K, versus its average volume of 213.46K.
The stock's 52-week range extends from a low of $0.49 to a high of $1.89.
The stock's 52-week range extends from a low of $0.49 to a high of $1.89.
Analyst ratings
100%
of 8 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own CNTX. This list is generated using Robinhood data, and it’s not a recommendation.